Latest Period
Q1 2026
Security Snapshot
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) Institutional Ownership
CUSIP: 28657F103
13F Institutional Holders and Ownership History from Q2 2023 to Q2 2026
Institutions Reporting
46
Shares (Excl. Options)
2,640,087
Price
$10.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.01 per share
- Symbol
- ELTX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,640,087
- Total 13F value
- $28,223,049
- Portfolio coverage rank
- 0%
- Share change
- +471,297
- Value change
- +$5,193,285
- Number of holders
- 46
- Shares outstanding
- 23,096,590
- SEC-reported price per share
- $3.91
- Insider filing price
- $3.91
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share is tracked under CUSIP 28657F103.
- 46 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 46 to 6 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $28,223,049 to $202,482.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 46 institutions filings for Q1 2026.
Security key
28657F103
Latest holder period
Q1 2026
13F holders
46
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
ELTX full holder history
Elicio Therapeutics, Inc. SEC filings
Elicio Therapeutics, Inc. company facts
Elicio Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28657F103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ELTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GKCC, LLC | 48% | $52,827,914 | 9,764,864 | Yekaterina Chudnovsky | 03 Jun 2025 | |||
| Chudnovsky Yekaterina | 48% | $49,543,175 | 9,657,539 | Yekaterina Chudnovsky | 05 Mar 2025 | |||
| Moti Investments LLC | 6.1% | $5,205,856 | 1,408,892 | Moti Investments LLC | 01 Jul 2026 | |||
| Knoll Capital Management, LLC | 5.3% | +2% | $16,894,681 | +$8,099,725 | 1,211,957 | +92% | Knoll Capital Management, LLC | 01 Jul 2026 |
| Actyus Private Equity SGIIC, S.A. | 1.6% | -76% | $3,142,199 | -$6,877,471 | 268,564 | -69% | Actyus Private Equity SGIIC, S.A. | 30 Sep 2025 |
As of 31 Mar 2026, 46 institutional investors reported holding 2,640,087 shares of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX). This represents 11% of the company’s total 23,096,590 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
11%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 2.7% | 630,915 | 0% | 3.7% | $6,744,481 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2% | 518,638 | 0% | 0% | $5,544,240 |
| Balyasny Asset Management L.P. | 1.1% | 244,814 | +76% | 0.01% | $2,617,062 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.59% | 135,164 | +2% | 0% | $1,445,466 |
| RENAISSANCE TECHNOLOGIES LLC | 0.53% | 121,631 | +333% | 0% | $1,300,235 |
| MILLENNIUM MANAGEMENT LLC | 0.4% | 92,762 | 0% | $991,626 | |
| MARSHALL WACE, LLP | 0.32% | 74,512 | -36% | 0% | $796,532 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.31% | 70,804 | +11% | 0% | $756,895 |
| VANGUARD FIDUCIARY TRUST CO | 0.3% | 69,189 | 0% | 0% | $739,630 |
| NORTHERN TRUST CORP | 0.26% | 59,734 | +13% | 0% | $638,556 |
| GOLDMAN SACHS GROUP INC | 0.25% | 57,818 | 0% | $618,074 | |
| 683 Capital Management, LLC | 0.24% | 56,442 | 0% | 0.06% | $603,365 |
| STATE STREET CORP | 0.22% | 50,620 | +9.3% | 0% | $541,128 |
| BlackRock, Inc. | 0.22% | 50,597 | +12% | 0% | $540,882 |
| UBS Group AG | 0.15% | 33,769 | +5.5% | 0% | $360,991 |
| MORGAN STANLEY | 0.14% | 32,404 | +123% | 0% | $346,399 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 0.13% | 30,051 | 0.13% | $321,245 | |
| CM Management, LLC | 0.11% | 25,000 | 0% | 0.22% | $267,250 |
| HRT FINANCIAL LP | 0.09% | 21,611 | 0% | $231,000 | |
| Hudson Bay Capital Management LP | 0.09% | 20,208 | 0% | $216,024 | |
| Brevan Howard Capital Management LP | 0.08% | 17,401 | 0% | $186,017 | |
| Quadrature Capital Ltd | 0.07% | 16,912 | -1.4% | 0% | $180,789 |
| CITADEL ADVISORS LLC | 0.07% | 15,978 | 0% | $170,805 | |
| BANK OF AMERICA CORP /DE/ | 0.07% | 15,333 | +1225% | 0% | $163,910 |
| MEYER HANDELMAN CO | 0.06% | 13,899 | 0% | 0% | $148,580 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 53,102 | $202,482 | -$26,380 | $3.91 | 6 |
| 2026 Q1 | 2,640,087 | $28,223,049 | +$5,193,285 | $10.69 | 46 |
| 2025 Q4 | 2,079,772 | $16,555,641 | +$1,116,140 | $7.96 | 37 |
| 2025 Q3 | 1,911,273 | $20,875,759 | +$5,121,932 | $10.94 | 28 |
| 2025 Q2 | 1,450,816 | $11,188,879 | -$640,781 | $7.72 | 21 |
| 2025 Q1 | 1,591,744 | $9,804,572 | +$7,009,113 | $6.16 | 24 |
| 2024 Q4 | 454,072 | $2,254,908 | -$189,626 | $5.10 | 17 |
| 2024 Q3 | 491,473 | $2,479,497 | -$395,067 | $5.03 | 18 |
| 2024 Q2 | 648,667 | $2,679,243 | +$952,436 | $4.11 | 19 |
| 2024 Q1 | 405,757 | $3,073,195 | +$531,181 | $7.60 | 17 |
| 2023 Q4 | 332,813 | $2,775,559 | +$9,460 | $8.34 | 17 |
| 2023 Q3 | 330,928 | $2,796,450 | +$381,643 | $8.45 | 17 |
| 2023 Q2 | 285,765 | $2,714,943 | +$2,714,943 | $9.50 | 15 |